Our commitment to environmental sustainability is one of the foundational elements of our corporate culture. In order to continue serving patients, we have to grow in a manner that respects the environment, operate in a transparent and ethical manner, foster sustainable growth, and be a force for positive change around the world.

Our 2022 Environmental, Social, and Governance (ESG) Report details our ESG goals, strategies, and progress and, equally important, our approach to working with a common purpose. In pursuit of our mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases, we are making meaningful progress in progressing our environmental, social and governance initiatives and health equity commitments.


Korab Zuka, Vice President Purpose/ESG, sits down with Giovanni Caforio, CEO Emeritus, to discuss the importance of ESG at BMS.

"I am immensely proud of the progress our teams have made toward achieving our ESG goals and am confident in the positive impact BMS will continue to have on our patients and the world."
Chris Boerner, PhD, Chief Executive Officer at Bristol Myers Squibb

2022 ESG highlights

As a leading biopharmaceutical company, we understand our responsibility extends well beyond discovery, development and delivery of innovative medicines.

Our evolving ESG strategy builds on a legacy of comprehensive and global sustainability efforts.


Inclusion and diversity

  clinical trial sites in diverse metro areas 

$1B  global spend with diverse-owned businesses

Environmental responsibility

Formally submitted commitment to the the Science Based Targets Initiative (SBTi), committing to achieve net-zero GHG emissions (scopes 1, 2, and 3) by no later than 2050

Health equity and access to healthcare

Distributed nearly $100M in grant funding to support programs and services, reaching more than 10 million people

For prior year ESG reports, please visit the links below: